
Impella CP[®] with SmartAssist[®]







Impella CP with SmartAssist

Features to Improve Hemodynamic Support and Ease of Use

Greater Hemodynamic Support


Confident positioning allows for sustained higher flows.

■ Peak flows up to 4.3 L/min

Confident Positioning

Hemodynamic sensors assist in managing and positioning Impella CP.

- ▲ Optical sensor senses aortic pressure
- ▲ Microaxial motor senses pressure difference between aorta and left ventricle



Maintain Arterial Access

Reaccess sheath allows for escalation of care and is designed to improve hemostasis.

- ▲ Allows access to the artery with up to a 0.035" guidewire
- ▲ 4 cm additional length

Simplified Set-up

Improve ease of use and faster set-up time.

- Reduction in set-up steps with fewer connections
- Single fluid line management in ICU



Advanced Pump Metrics

Designed to optimize pump management and assist in weaning

- ▲ Left-ventricular placement signal
- Displays Cardiac Power Output
- Displays trends of LVEDP and MAP to assist weaning

Cardiac Power Output: #1 Correlation to Mortality in AMI Cardiogenic Shock¹

▲ CPO (in watts) = (MAP x Cardiac Output) / 451

Impella CP with SmartAssist Heart Pump Specifications

PART NUMBER	DESCRIPTION			
0048-0003	Impella heart pump, 9 Fr catheter, 6 Fr pigtail, 14 Fr microaxial pump, Percutaneous insertion through the femoral artery			
0043-0003	Impella Controller Purge Cassettes, Box of 5			
0052-3046	14Fr Combo Introducer Kit containing 13cm and 25cm length sheaths			
0052-3005	0.018" x 260 cm PTFE Guidewire for Impella 2.5 and Impella CP			
Maximum Flow: 4.3 L/min		Maximum Mean: 3.7 L/min	Speed Range: 0 to 46,000 rpm	Interventional Length: 92-98cm

To learn more, visit www.HeartRecovery.com

High-Risk PCI

The Impella 2.5°, Impella CP° and Impella CP° with SmartAssist° Systems are temporary (≤ 6 hours) ventricular support devices indicated for use during high-risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5, Impella CP, and Impella CP with SmartAssist Systems in these patients may prevent hemodynamic instability, which can result from repeat episodes of reversible myocardial ischemia that occur during planned temporary coronary occlusions and may reduce periand post-procedural adverse events.

Cardiogenic Shock

The Impella 2.5°, Impella CP°, Impella CP° with SmartAssist°, Impella 5.0°, Impella 5.5° with SmartAssist° and Impella LD° Catheters, in conjunction with the Automated Impella Controller™ (collectively, "Impella® System Therapy"), are temporary ventricular support devices intended for short term use (≤ 4 days for the Impella 2.5, Impella CP, and the Impella CP with SmartAssist, and ≤ 14 days for the Impella 5.0, Impella 5.5 with SmartAssist and Impella LD) and indicated for the treatment of ongoing cardiogenic shock that occurs immediately (<48 hours) following acute myocardial infarction or open heart surgery or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures (including volume loading and use of pressors and inotropes, with or without IABP). The intent of Impella System Therapy is to reduce ventricular work and to provide the circulatory support necessary to allow heart recovery and early assessment of residual myocardial function.

Important Risk Information for Impella devices

CONTRAINDICATIONS

The Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, Impella 5.5 with SmartAssist and Impella LD are contraindicated for use with patients experiencing any of the following conditions: Mural thrombus in the left ventricle; Presence of a mechanical aortic valve or heart constrictive device; Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm² or less); Moderate to severe aortic insufficiency (echocardiographic assessment graded as ≥ +2); Severe peripheral arterial disease precluding placement of the Impella System; Significant right heart failure*; Combined cardiorespiratory failure*; Presence of an Atrial or Ventricular Septal Defect (including post-infarct VSD)*; Left ventricular rupture*; Cardiac tamponade* *This condition is

a contraindication for the cardiogenic shock indication only.

* This condition is a contraindication for the cardiogenic shock indication only.

POTENTIAL ADVERSE EVENTS

Acute renal dysfunction, Aortic valve injury, Bleeding, Cardiogenic shock, Cerebral vascular accident/Stroke, Death, Hemolysis, Limb ischemia, Myocardial infarction, Renal failure, Thrombocytopenia and Vascular injury.

Impella Connect°

INTENDED USE

Impella Connect* transfers a video image of the screen on the Automated Impella Controller™ to an authorized remote user. The transmitted image can be viewed by authorized remote users. The users can include the hospital's clinicians, Abiomed local support staff, and Clinical Support Center (CSC) team members

PRECAUTIONS

- Impella Connect is not intended to provide real-time information for monitoring patient status on the Automated Impella Controller.
- During use of the Impella Connect, there will be a delay between when an image appears on the controller screen and when it is displayed at a remote viewing location.
- The Impella Connect is not a source of patient alarms, nor is its use intended as a replacement for monitoring the controller's alarms.
- During use of the Impella Connect, receipt of the displayed controller information is not confirmed by the Automated Impella Controller, nor is the delivery of the displayed controller information to the authorized remote users guaranteed.
- The Impella Connect is not designed for use during transport.
- Radiated and conducted electromagnetic interference can affect the performance of the Impella Connect, causing a temporary loss of connectivity. To clear interference, either increase the distance between system components and the EMI source or turn off the EMI source. Any electromagnetic interference related to the Impella Connect will have no impact on any of the controller functional specifications.
- Portable and mobile RF communications equipment can affect medical electrical equipment.

In addition to the risks above, there are other **WARNINGS** and **PRECAUTIONS** associated with Impella devices. Visit http://www.abiomed.com/important-safety-information to learn more.



24/7 Impella Clinical Support and Technical Expertise 1-800-422-8666 (US)

www.abiomed.com www.impellaconnect.com ABIOMED, Inc. 22 Cherry Hill Drive, Danvers, MA 01923 USA Voice: 978-646-1400 Facsimile: 978-777-8411

